Company Filing History:
2 out of 5 
1 out of 2 
1 out of 1 Years Active: 2014-2021
Title: Xianhong Bai: Innovator in Monoclonal Antibody Development
Introduction
Xianhong Bai is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 3 patents, his work focuses on innovative methods for treating various diseases.
Latest Patents
One of Xianhong Bai's latest patents is titled "Anti-PD-1 monoclonal antibody and obtaining method therefor." This invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2, and CDR3, as well as the heavy chain CDR1, CDR2, and CDR3 of phage libraries from the preliminary screening. The high affinity anti-PD-1 monoclonal antibodies were selected, which have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. These antibodies can be used for treating tumors, inflammation, and autoimmune diseases.
Another significant patent is the "Method for obtaining high-yield, stable expression cell clones and antibody molecules obtained thereby." This method provides a way to obtain high-yield, stable expression cell clones from myeloma cell lines in a protein-free culture medium. The method is designed for the industrial production of a recombinant antibody and includes three stages: adapting to a protein-free culture medium, culturing cells at a low density, and gradually reducing a fat-rich supplement to a chemical culture medium; adapting to a protein-free culture medium, culturing cells at a high density, and using a perfusion fermentation system in a laboratory scale; and screening high-yield, stable expression cell clones from the cells after fermentation ends. The cell clone may be used to produce a humanized anti-NeuGcGM3 14F7 recombinant antibody.
Career Highlights
Xianhong Bai has worked with notable companies such as Beijing Dongfang Biotech Co., Ltd. and Beijing Jingyitaixiang Technology Development Co., Ltd. His experience in these organizations has contributed to his expertise in the field of biotechnology